Key Developments: AngioDynamics Inc (ANGO.O)

ANGO.O on Nasdaq

19.17USD
26 Dec 2014
Price Change (% chg)

$-0.02 (-0.10%)
Prev Close
$19.19
Open
$19.18
Day's High
$19.30
Day's Low
$19.09
Volume
73,767
Avg. Vol
302,765
52-wk High
$19.30
52-wk Low
$13.06

Search Stocks

Latest Key Developments (Source: Significant Developments)

Angiodynamics Inc receives FDA clearance for DuraMax Dialysis Catheter with BioFlo Technology to reduce Catheter-Related Thrombus
Friday, 7 Mar 2014 06:30am EST 

Angiodynamics Inc:U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.This marks third U.S. clearance of BioFlo product line in company's Vascular Access business.Indicated for use in attaining long-term vascular access for hemodialysis and apheresis, AngioDynamics expects a commercial launch in fourth quarter of fiscal year 2014.  Full Article

Angiodynamics Inc raises low end of prior FY 2014 revenue guidance; reaffirms FY 2014 EPS guidance; Q3 2014 guidance; EPS guidance above analysts' estimates
Thursday, 9 Jan 2014 04:05pm EST 

Angiodynamics Inc:Says as a result of stronger than anticipated H1 2014.Says for FY 2014 it is raising the low end of revenue guidance to $349 million to $353 million.Says for FY 2014 it expect to report adjusted EPS, excluding amortization, of $0.63 to $0.67 per share, which is consistent with its prior guidance.Says Q3 2014 revenue to range from $85 million to $88 million.Says Q3 2014 adjusted EPS, excluding amortization, is expected to be $0.15 to $0.18 per share.Q3 2014 revenue of $86 million and EPS of $0.10 - Thomson Reuters I/B/E/S Estimates.FY 2014 revenue of $351 million - Thomson Reuters I/B/E/S Estimates.  Full Article

Angiodynamics Inc Achieves CE Approval for AngioVac
Tuesday, 29 Oct 2013 06:30am EDT 

AngioDynamics announced EU CE Mark approval for its AngioVac venous drainage cannula and cardiopulmonary bypass circuit for use during extracorporeal bypass for up to six hours. Under the CE Mark approval the AngioVac cannula is also approved for removal of fresh, soft thrombi or emboli.  Full Article

Angiodynamics Inc Raises FY 2014 Guidance; Issues Q2 2014 Guidance; EPS Guidance Above Analysts' Estimates
Thursday, 10 Oct 2013 04:01pm EDT 

Angiodynamics Inc announced that for fiscal 2014, it is raising revenue expectations, following the recent distributor acquisition, to a range of $347 million to $353 million. As a result of debt refinance results, the Company is also increasing adjusted EPS without amortization to be $0.63-$0.67. For the second quarter of 2014, it expects revenue to range from $85 million to $88 million and adjusted EPS without amortization to be $0.12-$0.15. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $349 million and EPS of $0.32 for fiscal 2014; revenues of $87 million and $0.08 for the second quarter of 2014.  Full Article

Angiodynamics Inc Signs Multi-Year, Sole-Source Agreement With Integrated Delivery Network Group
Thursday, 10 Oct 2013 11:51am EDT 

Angiodynamics Inc announced that it has signed a sole-source, three-year port product agreement with the Integrated Delivery Network Group (LIDN), in order to transform supply chain services. Under the terms of the agreement, effective November 1, 2013, AngioDynamics' entire port line, including its new BioFlo Ports, will be available to approximately 130 hospitals in the group that utilize ports.  Full Article

Angiodynamics Inc Extends Licensing Agreement With Interface Biologics To Include Central Venous Catheters (CVCs)
Monday, 23 Sep 2013 06:30am EDT 

Angiodynamics Inc and Interface Biologics Inc announced that AngioDynamics' exclusive Endexo technology licensing agreement for peripherally inserted catheters (PICCs), ports and dialysis catheters, now includes Central Venous Catheters (CVCs). AngioDynamics' BioFlo PICCs with Endexo technology received U.S. Food and Drug Administration clearance in September 2012, and it is similarly approved in Europe and Canada. In August, the Company's BioFlo Port with Endexo technology also received FDA clearance.  Full Article

Angiodynamics Inc's Navilyst Medical Earns FDA Clearance For Ports With BioFlo Technology To Reduce Catheter Related Thrombus
Tuesday, 20 Aug 2013 06:30am EDT 

AngioDynamics Inc announced the U.S. Food and Drug Administration has granted 510(k) clearance to Navilyst Medical Inc., an AngioDynamics company, for its BioFlo Port with Endexo technology designed to reduce the accumulation of catheter-related thrombus on, and in, the port catheter. This marks the second U.S. clearance of a product line developed with BioFlo's advanced technology; an initial launch is expected in the Company's third quarter of fiscal year 2014.  Full Article

Angiodynamics Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates-Conference Call
Wednesday, 14 Aug 2013 05:00pm EDT 

Angiodynamics Inc announced that for fiscal 2014, it expects modest revenue growth of basically 1% to 3%. The Company reported revenue of $342.03 million for fiscal 2013. According to I/B/E/S estimates, analysts were expecting the Company to report revenue of $348.66 million for fiscal 2014.  Full Article

Angiodynamics Inc Issues FY 2014 Guidance In Line With Analysts' Estimates; Issues Q1 2014 Guidance; EPS Guidance Above Analysts' Estimates
Thursday, 11 Jul 2013 04:01pm EDT 

Angiodynamics Inc announced that for fiscal 2014, it expects to deliver modest sales growth ranging from $346 million to $352 million, reflecting a 3% increase at the top end of the range. Anticipate adjusted earnings per share (EPS) to be in the range of $0.31-$0.35 and adjusted EPS, excluding amortization, to be in the range of $0.61-$0.65. The Company expects net sales to range from $81 million to $84 million in the first quarter of 2014, Adjusted EPS is expected to be in the range of $0.02-$0.04 and in the range of $0.10-$0.12 for adjusted EPS excluding amortization. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $350 million and EPS of $0.33 for fiscal 2014; revenues of $84 million and $0.08 for the first quarter of 2014.  Full Article

Angiodynamics Inc Announces FDA Clearance For Xcela Plus Port Family With PASV Technology
Thursday, 27 Jun 2013 06:30am EDT 

AngioDynamics Inc announced it has received two key port product clearances. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Xcela Plus Port family, with Pressure Activated Safety Valve (PASV) technology to Navilyst Medical, an AngioDynamics Company. Additionally, AngioDynamics has received the Medical Device License from Health Canada to market and sell the Smart Port CT family of power-injectable ports, featuring Vortex port technology.  Full Article

Search Stocks